½ÃÀ庸°í¼­
»óǰÄÚµå
1670232

¾ËºÎ¹Î ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : À¯Çüº°, ¿ëµµº°, ÆÇ¸Å ä³Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)

Albumin Market Size, Share, and Growth Analysis, By Type (Human Serum Albumin, Bovine Serum Albumin), By Application (Therapeutics, Drug Formulation and Vaccines), By Sales Channel, By End-User, By Region - Industry Forecast 2025-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 188 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾ËºÎ¹Î ½ÃÀå ±Ô¸ð´Â 2023³â 66¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â 70¾ï 8,000¸¸ ´Þ·¯¿¡¼­ 2032³â 112¾ï 1,000¸¸ ´Þ·¯·Î ¼ºÀåÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È 5.9%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾ËºÎ¹Î ¼¼°è ½ÃÀåÀº Ç÷¾×·® Áõ°¡, °£ Áúȯ Ä¡·á, È­»ó °ü¸®¿Í °°Àº Áß¿äÇÑ ÀÇ·á ¿ëµµ·Î ÀÎÇØ Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. »ïÅõ¾Ð À¯Áö ¹× Çʼö ¹°Áú ¼ö¼Û°ú °°Àº ¾ËºÎ¹ÎÀÇ ÁÖ¿ä ±â´ÉÀº ¾ËºÎ¹ÎÀÇ Ä¡·á °¡´É¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â »ý¸íÀ» À§ÇùÇÏ´Â Áúº´ÀÇ À¯º´·ü Áõ°¡, ¿Ü°ú ¼ö¼úÀÇ Áõ°¡(2022³â Àü ¼¼°è ¼ö¼ú °Ç¼ö 3¾ï 1,000¸¸ °Ç), ºñÄ¡·áÀû ¿ëµµÀÇ Áõ°¡ µîÀ» µé ¼ö ÀÖÀ¸¸ç, GrifolsÀÇ °£°æº¯Áõ¿¡ ´ëÇÑ ¾ËºÎƾ Æò°¡, Shilpa BiologicalsÀÇ Ä£È¯°æ ÀçÁ¶ÇÕ Àΰ£ ¾ËºÎ¹Î°ú °°Àº Çõ½ÅÀûÀÎ ¹ßÀüÀº º¸´Ù È¿°úÀûÀ̰í Áö¼Ó°¡´ÉÇÑ Á¦Ç°À¸·ÎÀÇ ÀüȯÀ» ½Ã»çÇϰí ÀÖ½À´Ï´Ù. ¾ËºÎ¸Þµñ½º¿Í ¹Ù¸£³×¹ÙÀÇ ¹é½Å Á¦Á¦ °³¼±À» À§ÇÑ Çù·ÂÀº ÇコÄÉ¾î ¼Ö·ç¼ÇÀ» ¹ßÀü½Ã۰í Çʼö Ä¡·á¿¡ ´ëÇÑ Àü ¼¼°èÀÎÀÇ Á¢±Ù¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ ¾÷°èÀÇ ³ë·ÂÀ» º¸¿©ÁÝ´Ï´Ù.

¸ñÂ÷

¼Ò°³

  • Á¶»ç ¸ñÀû
  • Á¶»ç ¹üÀ§
  • Á¤ÀÇ

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀå °¡Á¤°ú Á¦ÇÑ

ÁÖ¿ä ¿ä¾à

  • ¼¼°è ½ÃÀå Àü¸Á
  • °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • Porters ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • Çٽɼº°ø¿äÀÎ
  • °æÀï Á¤µµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå »ýŰè
  • ½ÃÀå ¸Å·Â Áö¼ö(2024³â)
  • PESTEL ºÐ¼®
  • °Å½Ã°æÁ¦ ÁöÇ¥
  • ¹ë·ùüÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®
  • »ç·Ê ¿¬±¸
  • ±ÔÁ¦ »óȲ

¾ËºÎ¹Î ½ÃÀå ±Ô¸ð : À¯Çüº°

  • ½ÃÀå °³¿ä
  • Àΰ£ Ç÷û ¾ËºÎ¹Î
  • ¼Ò Ç÷û ¾ËºÎ¹Î
  • ÀçÁ¶ÇÕ ¾ËºÎ¹Î

¾ËºÎ¹Î ½ÃÀå ±Ô¸ð : ¿ëµµº°

  • ½ÃÀå °³¿ä
  • Ä¡·áÁ¦
  • ÀǾàǰ 󹿰ú ¹é½Å
  • ¹Ìµð¾î ±¸¼º¿ä¼Ò
  • ±âŸ ¿ëµµ

¾ËºÎ¹Î ½ÃÀå ±Ô¸ð : ÆÇ¸Å ä³Îº°

  • ½ÃÀå °³¿ä
  • ±â¾÷ ´ë ¼ÒºñÀÚ(B2C)
  • ±â¾÷°£ °Å·¡(B2B)

¾ËºÎ¹Î ½ÃÀå ±Ô¸ð : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå °³¿ä
  • º´¿ø°ú Áø·á¼Ò
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • Á¶»ç±â°ü

¾ËºÎ¹Î ½ÃÀå ±Ô¸ð

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï Á¤º¸

  • »óÀ§ 5°³»çÀÇ ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤¿ëÇÑ Àü·«
  • ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • ±â¾÷ »ó¼¼
    • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
    • ±â¾÷ ºÎ¹®º° Á¡À¯À² ºÐ¼®
    • ¸ÅÃâ Àü³âºñ ºñ±³(2022-2024³â)

ÁÖ¿ä ±â¾÷ °³¿ä

  • Merck KGaA(Germany)
  • CSL Limited(Australia)
  • Grifols S.A.(Spain)
  • Baxter International Inc.(USA)
  • China Biologic Products Holdings, Inc.(China)
  • Takeda Pharmaceuticals(Japan)
  • Octapharma AG(Switzerland)
  • Novozymes A/S(Denmark)
  • Thermo Fisher Scientific Inc.(USA)
  • Ventria Bioscience(USA)
  • Albumedix Ltd.(UK)
  • Biotest AG(Germany)
  • HiMedia Laboratories(India)
  • Invitria(USA)
  • Medxbio Pte Ltd.(Singapore)
  • RayBiotech, Inc.(USA)
  • SeraCare(USA)
  • Kedrion S.p.A.(Italy)
  • Albumin Therapeutics, LLC(USA)

°á·Ð°ú Á¦¾È

ksm 25.04.10

Albumin Market size was valued at USD 6.69 billion in 2023 and is poised to grow from USD 7.08 billion in 2024 to USD 11.21 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The global albumin market is poised for significant growth due to its critical medical applications in increasing blood volume, treating liver diseases, and managing burn injuries. Key functions of albumin, such as maintaining osmotic pressure and transporting essential substances, enhance its therapeutic potential. Driving factors include the rising prevalence of life-threatening diseases, an increase in surgical procedures-310 million surgeries were performed globally in 2022-and an uptick in non-therapeutic uses. Innovative advancements, like Grifols' evaluation of Albutein for cirrhosis, and Shilpa Biologicals' environmentally friendly recombinant Human Albumin, signal a shift towards more effective and sustainable products. Collaborations, like that of Albumedix with Valneva to improve vaccine formulations, represent the industry's commitment to advancing healthcare solutions and boosting global access to essential treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Albumin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Albumin Market Segments Analysis

Global Albumin Market is segmented by Type, Application, Sales Channel, End-User and region. Based on Type, the market is segmented into Human Serum Albumin, Bovine Serum Albumin and Recombinant Albumin. Based on Application, the market is segmented into Therapeutics, Drug Formulation and Vaccines, Component of Media and Other Applications. Based on Sales Channel, the market is segmented into Business-To-Consumer (B2C) and Business-To-Business (B2B). Based on End-User, the market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Albumin Market

The albumin market is driven by several key factors, notably the rising demand for albumin in regenerative medicine, vaccine stabilization, and drug formulations. Its significance in contemporary biopharmaceuticals is highlighted by its applications in plasma expansion, drug delivery systems, and nanomedicine. Additionally, the increasing prevalence of chronic diseases, including conditions such as hypovolemia and liver disorders, is prompting pharmaceutical companies to innovate and develop new therapeutic drugs. This growing patient population necessitates advanced treatments, further stimulating the demand for albumin and enhancing its role as a crucial component in various medical applications and drug formulations.

Restraints in the Albumin Market

The albumin market faces significant challenges due to the intricate and costly production processes, particularly for recombinant albumin. The extensive reliance on plasma collection results in complexities surrounding purification and quality control for plasma-derived albumin. Additionally, the operational costs are heightened by fluctuations in plasma supply, stringent regulatory approval processes, and the necessity for cold-chain logistics. These factors collectively impede accessibility and affordability, particularly in developing regions, ultimately acting as major restraints on the albumin market's growth and expansion potential, affecting both manufacturers and end-users alike.

Market Trends of the Albumin Market

The albumin market is experiencing a notable shift towards sustainable production methods, with a growing emphasis on recombinant albumin. Concerns surrounding plasma sourcing, potential pathogen transmission, and supply chain vulnerabilities are driving companies to invest in genetic engineering technologies. This transition is yielding innovative alternatives, including plant-based and yeast-expressed recombinant albumin, which promise enhanced safety and environmental sustainability. As the industry pivots away from traditional plasma-derived products, these advancements not only address contamination risks but also offer cost-effective solutions that appeal to both manufacturers and consumers. This trend underscores a broader commitment to safety and sustainability in biopharmaceutical manufacturing.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Regulatory Landscape

Global Albumin Market Size by Type & CAGR (2025-2032)

  • Market Overview
  • Human Serum Albumin
  • Bovine Serum Albumin
  • Recombinant Albumin

Global Albumin Market Size by Application & CAGR (2025-2032)

  • Market Overview
  • Therapeutics
  • Drug Formulation and Vaccines
  • Component of Media
  • Other Applications

Global Albumin Market Size by Sales Channel & CAGR (2025-2032)

  • Market Overview
  • Business-To-Consumer (B2C)
  • Business-To-Business (B2B)

Global Albumin Market Size by End-User & CAGR (2025-2032)

  • Market Overview
  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Research Institutes

Global Albumin Market Size & CAGR (2025-2032)

  • North America (Type, Application, Sales Channel, End-User)
    • US
    • Canada
  • Europe (Type, Application, Sales Channel, End-User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type, Application, Sales Channel, End-User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type, Application, Sales Channel, End-User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type, Application, Sales Channel, End-User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CSL Limited (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Grifols S.A. (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • China Biologic Products Holdings, Inc. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceuticals (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Octapharma AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novozymes A/S (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Thermo Fisher Scientific Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ventria Bioscience (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Albumedix Ltd. (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biotest AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • HiMedia Laboratories (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Invitria (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medxbio Pte Ltd. (Singapore)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • RayBiotech, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • SeraCare (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kedrion S.p.A. (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Albumin Therapeutics, LLC (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦